CCR6 and inflammatory bowel disease: Inhibition of CCL20-mediated cell chemotaxis and antimicrobial activity may in fact enhance susceptibility to infections, further promoting the circuit of dysbiosis and chronic inflammation behind IBD pathogenesis, suggesting that blocking CCR6-CCL20 axis may not be a long-term effective therapeutic approach to IBD [59,60].